Inspire Medical Systems (INSP Quick QuoteINSP - Free Report) reported $206.7 million in revenue for the quarter ended September 2026, representing a year-over-year decline of 7.9%. EPS of $0.14 for the same period compares to $0.38 a year ago.

The reported revenue represents a surprise of +1.17% over the Zacks Consensus Estimate of $204.3 million. With the consensus EPS estimate being $0.10, the EPS surprise was +40%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Inspire performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total U.S. sales territories: 279 compared to the 287 average estimate based on two analysts.
• Geographic Revenue- International: $9.21 million compared to the $11.87 million average estimate based on four analysts. The reported number represents a change of -8.9% year over year.
• Geographic Revenue- United States: $197.49 million versus $192.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -7.9% change.

View all Key Company Metrics for Inspire here>>>

Shares of Inspire have returned -2.7% over the past month versus the Zacks S&P 500 composite's -0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.